Patent No. US10662468 (titled "Spatially encoded biological assays") on Oct 22, 2019. The application was issued on May 26, 2020.
’468 is related to the field of spatially encoded biological assays and high-resolution molecular mapping. It specifically addresses the challenge of simultaneously measuring the abundance and distribution of numerous biological targets, such as nucleic acids and proteins, within a solid tissue sample while preserving the original spatial context of those molecules.
The underlying idea behind ’468 is the decoupling of target detection from spatial localization through a digital encoding scheme. Instead of relying on physical separation or visual microscopy alone, the invention uses coding tags—unique oligonucleotide sequences—that act as coordinate markers. By linking these location-specific tags to probes that capture biological targets, the system converts spatial information into a digital sequence format that can be processed in bulk.
The claims of ’468 focus on a method for determining the presence or abundance of a nucleic acid at a specific location in a tissue section using an array of capture agents. Each capture agent is a chimeric molecule featuring a sequence that specifically binds a target nucleic acid and a second sequence containing a coding tag that identifies the agent's precise position on the array.
In practice, the tissue section is placed in contact with the array, allowing the capture agents to hybridize with the target molecules in the sample. Once the targets are bound, the combined genetic information—the identity of the target and its corresponding spatial tag—is read out using high-throughput sequencing. This allows the researcher to pool all the data into a single reaction while retaining the ability to computationally map every molecule back to its exact origin in the tissue.
This approach differs from prior methods like laser capture microdissection or standard in situ hybridization by offering massive scalability and a digital readout. By using a combinatorial grid of tags, the system can resolve thousands of different targets across millions of locations simultaneously. This eliminates the labor-intensive physical handling of tissue fragments and provides a quantitative, high-resolution map of cellular function that was previously unattainable.
In the early 2010s when ’468 was filed, the analysis of biological molecules in tissue samples was typically implemented using techniques such as in situ hybridization or laser capture microdissection. At a time when systems commonly relied on the physical transference of tissue into discrete wells or the manual isolation of small cell populations to preserve spatial context, hardware and software constraints made the simultaneous measurement of high-plex gene or protein expression across large, contiguous spatial areas non-trivial. Consequently, standard practices often forced a trade-off between achieving high levels of multiplexing and maintaining the high-resolution spatial architecture of the original biological specimen.
The disclosed invention represents a meaningful technical advancement through an architectural shift in spatial biology that integrates multiplexed molecular assays with a digital encoding scheme. By delivering encoded probes to a sample in defined spatial patterns—where each probe contains a coding tag identifying its delivery location—the system enables the pooling of assay products for high-throughput sequencing while retaining the ability to map results back to specific coordinates. This integration overcomes the technical constraint of low spatial resolution inherent in physical tissue partitioning, enabling the simultaneous digital quantification of thousands of biological targets across a sample surface without sacrificing the underlying structural context of the tissue.
This patent contains 30 claims, with claim 1 being the sole independent claim. The independent claim focuses on a method for determining the presence or abundance of a nucleic acid at a specific location within a tissue section by using an array of capture agents that include both a binding sequence and a location-specific coding tag. The dependent claims serve to specify various technical parameters and process variations, such as the types of nucleic acids and tissue sections used, the physical structure of the array features, specific biochemical steps like amplification and sequencing, and the density of capture agents and features on the array.
Definitions of key terms used in the patent claims.
US Latest litigation cases involving this patent.

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Get instant alerts for new documents